Multiple therapeutic modalities were explored in terms of NF-κΒ inhibition for lymphoid neoplasms by directly targeting NF-κB components or indirectly by inhibiting upstream signaling pathways’ components (reviewed in [239]). Here, NFKB1 is linked to lymphoid neoplasm.